Business Description
Allogene Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US0197701065
Description
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.72 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | -0.32 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.56 | |||||
| Beneish M-Score | -3.67 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 2.8 | |||||
| 3-Year EPS without NRI Growth Rate | 8.6 | |||||
| 3-Year FCF Growth Rate | -0.5 | |||||
| 3-Year Book Growth Rate | -26.6 | |||||
| Future 3-5Y Total Revenue Growth Rate | 19.41 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.94 | |||||
| 9-Day RSI | 23.51 | |||||
| 14-Day RSI | 30.88 | |||||
| 6-1 Month Momentum % | 36.2 | |||||
| 12-1 Month Momentum % | -12.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.38 | |||||
| Quick Ratio | 12.38 | |||||
| Cash Ratio | 12.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.3 | |||||
| Shareholder Yield % | -0.49 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -331044.21 | |||||
| Net Margin % | -344489.47 | |||||
| FCF Margin % | -251841.05 | |||||
| ROE % | -54.96 | |||||
| ROA % | -44.29 | |||||
| ROIC % | -120.95 | |||||
| ROC (Joel Greenblatt) % | -171 | |||||
| ROCE % | -45.55 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3460 | |||||
| PB Ratio | 1.14 | |||||
| Price-to-Tangible-Book | 1.13 | |||||
| EV-to-EBIT | -0.77 | |||||
| EV-to-EBITDA | -0.8 | |||||
| EV-to-Revenue | 2543.45 | |||||
| EV-to-Forward-Revenue | 4832.56 | |||||
| EV-to-FCF | -1.01 | |||||
| Price-to-Net-Current-Asset-Value | 1.77 | |||||
| Price-to-Net-Cash | 1.83 | |||||
| Earnings Yield (Greenblatt) % | -129.87 | |||||
| FCF Yield % | -40.89 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALLO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Allogene Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.095 | ||
| EPS (TTM) ($) | -2.12 | ||
| Beta | 0.53 | ||
| Volatility % | 69.35 | ||
| 14-Day RSI | 30.88 | ||
| 14-Day ATR ($) | 0.270645 | ||
| 20-Day SMA ($) | 4.0785 | ||
| 12-1 Month Momentum % | -12.6 | ||
| 52-Week Range ($) | 2.23 - 6.89 | ||
| Shares Outstanding (Mil) | 169.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Allogene Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Allogene Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Allogene Therapeutics Inc Frequently Asked Questions
What is Allogene Therapeutics Inc(ALLO)'s stock price today?
The current price of ALLO is $3.45. The 52 week high of ALLO is $6.89 and 52 week low is $2.23.
When is next earnings date of Allogene Therapeutics Inc(ALLO)?
The next earnings date of Allogene Therapeutics Inc(ALLO) is 2024-05-03 Est..
Does Allogene Therapeutics Inc(ALLO) pay dividends? If so, how much?
Allogene Therapeutics Inc(ALLO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers